Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung‐Ju Ahn, Jaafar Bennouna, Kentaro Tanaka et al.|Journal of Clinical Oncology|2024Cited by 177
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Rebecca S. Heist, Jacob Sands et al.|Journal of Clinical Oncology|2023Cited by 168
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Funda Meric‐Bernstam, Ian E. Krop et al.|Journal of Clinical Oncology|2024Cited by 158
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunityRamin Salehi‐Rad, Steven M. Dubinett, Raymond J. Lim et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 30
Characteristics of a <i>CCL21</i> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung CancerMichael S. Oh, Bin Liu, Camelia Dumitras et al.|Molecular Cancer Therapeutics|2024Cited by 10